Drugs to Prevent Bronchopulmonary Dysplasia: Effect of Baseline Risk on the Number Needed to Treat - 27/01/21
Doi : 10.1016/j.jpeds.2020.01.070
Erik A. Jensen, MD, MSCE 1, 2, ⁎ 
, Robin S. Roberts, MSc 3, Barbara Schmidt, MD, MSc 2, 3
, Robin S. Roberts, MSc 3, Barbara Schmidt, MD, MSc 2, 3 1 Division of Neonatology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA
2 Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
3 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
∗Reprint requests: Erik A. Jensen, MD, MSCE, Children's Hospital of Philadelphia, Suite 2NW21, 34th and Civic Center Blvd, Philadelphia, PA 19104.Children's Hospital of PhiladelphiaSuite 2NW2134th and Civic Center BlvdPhiladelphiaPA19104
Abstract |
Infants born very preterm have a variable baseline risk of bronchopulmonary dysplasia (BPD). Using the example of evidence-based drug therapies to prevent BPD, we designed a visual aid that displays the “number needed to treat” with CIs for caffeine, vitamin A, and hydrocortisone over a range of baseline risks.
Le texte complet de cet article est disponible en PDF.Keywords : baseline risk, NNT, evidence-based medicine, caffeine, vitamin A, hydrocortisone, chronic lung disease
Abbreviations : BPD, NNT, RD
Plan
| The authors declare no conflicts of interest. |
© 2020
Elsevier Inc. Tous droits réservés.
Vol 222
P. 244-247 - juillet 2020 Retour au numéro
Article précédent
- Maternal Autoimmune Disorders and Risk of Kawasaki Disease in Offspring
- Sabrina Belkaibech, Brian J. Potter, Harb Kang, Ga Eun Lee, Marianne Bilodeau-Bertrand, Nathalie Auger
- Tinea Capitis: Bedside Diagnosis by Dermoscopy
- Avik Panigrahi, Abheek Sil, Surajit Kumar Biswas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?